“Only buy something that you’d be perfectly happy to hold if the market shut down for 10 years.”
— Warren Buffett
The Warren Buffett investment philosophy calls for a long-term investment horizon, where a decade-long holding period, or even longer, fits comfortably within the strategy. For investors who embrace that approach, one practical question is how a buy-and-hold position in a specific stock has actually performed over a full 10-year cycle.
Here, we examine how that philosophy would have worked out for an investment in Humana Inc. (NYSE: HUM), a major U.S. health insurer and Medicare Advantage provider. The analysis below looks at the outcome of a hypothetical $10,000 investment made in early April 2016 and held through early April 2026, with all dividends reinvested via a dividend reinvestment plan (DRIP).
| Start date: | 04/04/2016 |
|
|||
| End date: | 04/01/2026 | ||||
| Start price/share: | $185.47 | ||||
| End price/share: | $176.95 | ||||
| Starting shares: | 53.92 | ||||
| Ending shares: | 58.63 | ||||
| Dividends reinvested/share: | $26.63 | ||||
| Total return: | 3.74% | ||||
| Average annual return: | 0.37% | ||||
| Starting investment: | $10,000.00 | ||||
| Ending investment: | $10,376.12 | ||||
The analysis above shows that a decade-long investment in Humana, with dividends reinvested, translated into an annualized rate of return of 0.37%. In dollar terms, a $10,000 lump-sum investment made 10 years ago would have grown to $10,376.12 as of 04/01/2026.
That modest 3.74% total return over a full decade stands in contrast to the long-run performance that many investors may associate with U.S. equities more broadly. For context, over the same 10-year window, broad U.S. equity benchmarks such as the S&P 500 delivered substantially higher annualized returns, aided by strong gains from large-cap technology and communication services names. In relative terms, therefore, Humana significantly underperformed the wider market over this specific holding period, despite operating in a defensive sector traditionally viewed as resilient.
Understanding The Role Of Dividends In HUM’s Return
Dividends are always an important investment factor to consider, and Humana Inc. has paid $26.63 per share in dividends to shareholders over the 10-year period reviewed above. For income-oriented investors, this stream of cash flow can be a key component of the investment thesis, especially in lower-growth share-price environments.
Many investors will only consider stocks that pay regular dividends, so this component of total return is always worth careful analysis. In this hypothetical scenario, all dividends were automatically reinvested into additional shares of Humana through a DRIP. That reinvestment increased the investor’s share count from 53.92 at the start of the period to 58.63 by the end, helping offset a share price that finished below its level 10 years earlier.
Automated reinvestment of dividends into additional shares can be a powerful way for an investor to compound returns over time. When share prices are volatile or temporarily depressed, reinvested dividends can purchase more shares, which in turn can enhance future income as the company raises its dividend over time. The above calculations assume that all dividends received over the period were reinvested, and that the reinvestment price was the closing price on the ex-dividend date.
Current Yield Versus Yield On Cost
Based upon the most recent annualized dividend rate of $3.54 per share, we calculate that HUM has a current yield of approximately 2.00%. This compares with the yield available on U.S. Treasury securities and investment-grade corporate bonds over the same period, providing a reference point for investors deciding between equity income and fixed income alternatives.
Another useful datapoint is “yield on cost” — that is, the current annualized dividend expressed as a percentage of the original purchase price per share. When we take the current $3.54 annual dividend and divide it by the original $185.47 per share entry price, we arrive at a yield on cost of 1.08%.
Yield on cost does not determine today’s market valuation, but it does highlight how effectively a company has grown its dividend relative to the price an investor originally paid. In this case, Humana’s yield on cost remains relatively modest after a decade, underscoring that the company is still viewed primarily as a managed-care growth business rather than a high-yield income stock.
Business Context Over The 2016‑2026 Period
Over the last decade, Humana has operated against a complex backdrop of U.S. healthcare policy changes, reimbursement pressures, and demographic tailwinds linked to an aging population. The company is one of the largest providers of Medicare Advantage plans, a segment that has grown steadily as enrollment in privately managed Medicare options has expanded.
That structural demand has, at various points, been offset by rising medical cost trends, evolving regulatory frameworks, and competitive pressures from other managed-care organizations. In addition, the sector has navigated heightened volatility around proposed changes to Medicare Advantage payment rates and risk-adjustment methodologies, which can affect earnings visibility and investor sentiment.
Humana has also been active on the capital allocation front, combining dividend payments with share repurchases and investments in services businesses aligned with value-based care. For long-term shareholders, the balance between growth investments, buybacks, and cash dividends has been an important driver of per-share results.
Lessons For Long-Term Investors
The 10-year HUM case study illustrates that even companies with durable franchises can deliver periods of muted equity returns, particularly when valuation at the starting point is elevated, or when earnings growth fails to fully meet market expectations. A long-term horizon does not, by itself, guarantee strong outcomes; purchase price, business quality, and capital allocation all matter.
For investors employing a Buffett-style approach, one practical takeaway is the importance of reassessing the investment thesis periodically, even for positions initially intended to be held for a decade or longer. Monitoring fundamentals such as membership growth, medical loss ratios, returns on capital, and balance-sheet strength can help determine whether a stock continues to merit that kind of long holding period.
It is also worth noting that the 2016‑2026 period included significant macroeconomic and market events — including the COVID‑19 pandemic, shifting interest-rate regimes, and substantial rotations between growth and value factors. For a single stock such as Humana, those forces can compound company-specific developments, leading to return paths that look very different from headline indices.
The figures cited here were computed with the Dividend Channel DRIP Returns Calculator, which assumes dividend reinvestment and does not incorporate taxes, transaction costs, or other investor-specific frictions. Actual realized results for any individual investor would depend on trade execution, tax circumstances, and whether dividends were in fact reinvested.
Looking ahead, the key question for prospective and current shareholders is how HUM shares might perform over the next 10 years. Future returns will be shaped by factors including Medicare Advantage enrollment trends, regulatory changes, the trajectory of medical costs, and management’s ability to compound earnings per share and grow the dividend over time.
One more piece of investment wisdom to leave you with:
“History provides a crucial insight regarding market crises: they are inevitable, painful and ultimately surmountable.” — Shelby Davis
